114
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study

, , , , , ORCID Icon, ORCID Icon, , , & ORCID Icon show all
Pages 5597-5606 | Published online: 14 Sep 2021

References

  • Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-center, randomized, controlled trial. MedRxiv. 2020. https://www.semanticscholar.org/paper/Effect-of-Hydroxychloroquine-in-Hospitalized-with-a-Horby-Mafham/9019fe8a10a26e412af464eda3a54320ed179dbf
  • Furtado RH, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967. doi:10.1016/S0140-6736(20)31862-6
  • Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
  • Nasir M, Perveen RA, Saha SK, Talha KA, Selina F, Islam MA. Systematic review on repurposing use of Favipiravir against SARS-CoV-2. Mymensingh Med J. 2020;29(3):747–754.
  • Lu R. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2019:395(10224):566–568.
  • Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.01047
  • Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
  • Commission NH. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 8); 2020.
  • Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4#:~:text=Conclusions%20Among%20patients%20with%20COVID,Favipiravir%20are%20mild%20and%20manageable.
  • Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192–1198. doi:10.1016/j.eng.2020.03.007
  • Saudi MoH protocol for patients suspected of/confirmed with COVID‐19 supportive care and antiviral treatment of suspected or confirmed COVID‐19 infection (version 1.4) AtS; 2020 Available from: https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/covid19.aspx. Accessed September 3, 2021.
  • Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ. 2020;49(1):215–219
  • Tablet A. 200 mg. Report on the Deliberation Results. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. Ministry of Health. Labour and Welfare; 2014.
  • Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multi-center observational study. MedRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.06.24.20133249v3
  • Perveen RA, Nasir M, Murshed M, Nazneen R, Ahmad SN. Remdesivir and favipiravir changes hepato-renal profile in COVID-19 patients: a cross sectional observation in Bangladesh. Int J Med Sci Clin Invent. 2021;8(1):5196–5201. doi:10.18535/ijmsci/v8i01.03
  • Kaur RJ, Charan J, Dutta S, et al. Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infect Drug Resist. 2020;13:4427. doi:10.2147/IDR.S287934
  • Dabbous HM, El-Sayed MH, El Assal G, et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: a randomised controlled trial. Sci Rep. 2021;11(1):1–7. doi:10.1038/s41598-021-85227-0
  • Lagier J-C, Million M, Gautret P, et al. Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis. 2020;36:101791. doi:10.1016/j.tmaid.2020.101791
  • Guner R, Hasanoglu I, Kayaaslan B, et al. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. J Infect Public Health. 2021;14(3):365–370. doi:10.1016/j.jiph.2020.12.017
  • Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multi-center, Phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71. doi:10.1016/j.ijid.2020.11.142
  • Alzeer A, BaHammam A, Masood M, Basha SJ, Alhamad E, Sohail S. Outcome of patients with severe asthma in the intensive care unit. Ann Saudi Med. 2006;26(6):461–465. doi:10.5144/0256-4947.2006.461
  • Mamary AJ, Kondapaneni S, Vance GB, Gaughan JP, Martin UJ, Criner GJ. Survival in patients receiving prolonged ventilation: factors that influence outcome. Clin Med Insights Circ Respir Pulm Med. 2011;5:S6649.
  • Thai PQ, Son DT, Van HTH, et al. Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: a survival analysis. Epidemiol Infect. 2020;148. https://pubmed.ncbi.nlm.nih.gov/32517822/
  • Madelain V, Nguyen THT, Olivo A, et al. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016;55(8):907–923. doi:10.1007/s40262-015-0364-1
  • Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2020;102:501–508. doi:10.1016/j.ijid.2020.10.069
  • Chen C-Y, Wang F-L, Lin -C-C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clinical Toxicol. 2006;44(2):173–175.
  • Negoescu A, Thornback A, Wong E, Ostor A. Long QT and hydroxychloroquine; A poorly recognised problem in rheumatology patients.: 2045. Arthritis Rheum. 2013;65. https://acrabstracts.org/abstract/long-qt-and-hydroxychloroquine-a-poorly-recognised-problem-in-rheumatology-patients/
  • Çap M, Bilge Ö, Işık F, et al. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019. J Electrocardiol. 2020;63:115–119. doi:10.1016/j.jelectrocard.2020.10.015
  • Kumagai Y, Murakawa Y, Hasunuma T, et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther. 2015;53(10):866–874. doi:10.5414/CP202388